AmCad BioMed Statistics
Total Valuation
AmCad BioMed has a market cap or net worth of TWD 699.83 million. The enterprise value is 447.73 million.
Important Dates
The next estimated earnings date is Friday, February 26, 2027.
| Earnings Date | Feb 26, 2027 |
| Ex-Dividend Date | n/a |
Share Statistics
AmCad BioMed has 63.33 million shares outstanding. The number of shares has increased by 0.09% in one year.
| Current Share Class | 63.33M |
| Shares Outstanding | 63.33M |
| Shares Change (YoY) | +0.09% |
| Shares Change (QoQ) | -2.62% |
| Owned by Insiders (%) | 6.64% |
| Owned by Institutions (%) | 0.95% |
| Float | 31.63M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 26.75 |
| PB Ratio | 1.36 |
| P/TBV Ratio | 1.52 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 17.11 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 16.57, with a Debt / Equity ratio of 0.02.
| Current Ratio | 16.57 |
| Quick Ratio | 15.36 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -345.68 |
Financial Efficiency
Return on equity (ROE) is -12.09% and return on invested capital (ROIC) is -9.36%.
| Return on Equity (ROE) | -12.09% |
| Return on Assets (ROA) | -9.05% |
| Return on Invested Capital (ROIC) | -9.36% |
| Return on Capital Employed (ROCE) | -15.34% |
| Weighted Average Cost of Capital (WACC) | 6.17% |
| Revenue Per Employee | 769,471 |
| Profits Per Employee | -1.64M |
| Employee Count | 34 |
| Asset Turnover | 0.04 |
| Inventory Turnover | 0.74 |
Taxes
In the past 12 months, AmCad BioMed has paid 12,000 in taxes.
| Income Tax | 12,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -27.30% in the last 52 weeks. The beta is 0.36, so AmCad BioMed's price volatility has been lower than the market average.
| Beta (5Y) | 0.36 |
| 52-Week Price Change | -27.30% |
| 50-Day Moving Average | 14.28 |
| 200-Day Moving Average | 12.49 |
| Relative Strength Index (RSI) | 28.79 |
| Average Volume (20 Days) | 396,634 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, AmCad BioMed had revenue of TWD 26.16 million and -55.64 million in losses. Loss per share was -0.88.
| Revenue | 26.16M |
| Gross Profit | 5.87M |
| Operating Income | -90.57M |
| Pretax Income | -71.99M |
| Net Income | -55.64M |
| EBITDA | -79.89M |
| EBIT | -90.57M |
| Loss Per Share | -0.88 |
Full Income Statement Balance Sheet
The company has 331.64 million in cash and 12.18 million in debt, with a net cash position of 319.46 million or 5.04 per share.
| Cash & Cash Equivalents | 331.64M |
| Total Debt | 12.18M |
| Net Cash | 319.46M |
| Net Cash Per Share | 5.04 |
| Equity (Book Value) | 582.78M |
| Book Value Per Share | 8.36 |
| Working Capital | 341.00M |
Full Balance Sheet Cash Flow
| Operating Cash Flow | -51.98M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 10.67M |
| Net Borrowing | -4.69M |
| Free Cash Flow | -51.98M |
| FCF Per Share | -0.82 |
Full Cash Flow Statement Margins
Gross margin is 22.42%, with operating and profit margins of -346.18% and -212.67%.
| Gross Margin | 22.42% |
| Operating Margin | -346.18% |
| Pretax Margin | -275.18% |
| Profit Margin | -212.67% |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
AmCad BioMed does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -0.09% |
| Shareholder Yield | -0.09% |
| Earnings Yield | -7.96% |
| FCF Yield | -7.43% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |